Form 4: Axsome Therapeutics CEO Sells Shares Under 10b5-1 Plan

Axsome Therapeutics CEO Herriot Tabuteau executed a 10b5-1 plan transaction on July 1, 2026, involving the exercise of stock options and subsequent sale of shares.

Summary

• Herriot Tabuteau, CEO of Axsome Therapeutics, engaged in a transaction on July 1, 2026, involving the exercise of stock options and the sale of the underlying common stock.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• The exercise involved 49,666 stock options with an exercise price of $4.95 per share.
• The sale of the underlying shares occurred at a weighted average price of $240.25 per share, with individual sale prices ranging from $237.64 to $244.71.
• Following these transactions, Tabuteau's direct beneficial ownership of common stock is 7,229 shares.
• An additional 7,344,500 shares are held indirectly, with Tabuteau retaining voting and dispositive power over these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by the CEO could be perceived negatively, the execution under a 10b5-1 plan mitigates concerns about insider trading and suggests a planned financial strategy rather than a lack of confidence in the company.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies designed to avoid insider trading concerns.
• The exercise of options suggests that the options were in-the-money, reflecting a potential gain for the executive.
• The weighted average sale price of $240.25 per share indicates a significant valuation for Axsome Therapeutics' stock at the time of the transaction.

Negatives

• The CEO sold a substantial number of shares (49,666), which could be interpreted negatively by the market, despite being part of a pre-planned strategy.
• The exercise of options and immediate sale of shares might suggest a lack of confidence in further short-term price appreciation, although this is mitigated by the 10b5-1 plan.

Risks

• The filing does not explicitly mention any new risks. However, the sale of shares by a key executive, even under a 10b5-1 plan, could be perceived as a negative signal by investors, potentially impacting stock price.
• The expiration of stock options due to reaching their 10-year term is a standard event but highlights the time-bound nature of executive compensation.

Future Outlook

The filing itself is a report of past transactions and does not contain forward-looking statements or guidance. The nature of the transaction under a 10b5-1 plan suggests a pre-determined strategy for managing executive stock holdings.

Management Comments

• The exercise of stock options was necessary due to the attainment of the 10-year expiration date.
• The transaction was executed pursuant to a pre-approved 10b5-1 plan.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting transactions under Rule 10b5-1 plans are common for executives in the biopharmaceutical sector. These plans allow executives to diversify their holdings or meet financial obligations without triggering insider trading concerns, especially during periods of significant stock price appreciation or volatility common in the industry.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by the CEO, even under a 10b5-1 plan, as a potential signal, though the plan's existence provides a degree of reassurance.
• Employees: The transaction does not directly impact employee stock options or compensation but reflects the financial activities of senior leadership.
• Management: The transaction is a personal financial management activity for the CEO, executed within regulatory guidelines.

Next Steps

• The reporting person will continue to hold any remaining shares beneficially owned.
• Future transactions, if any, will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Beneficial Ownership, Executive Compensation, Securities Trading